Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib/Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus

Next Previous
Search
Trial Profile

A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib/Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lonafarnib (Primary) ; Ritonavir
  • Indications Hepatitis D
  • Focus Adverse reactions
  • Acronyms LOWR HDV - 4; LOWR-4
  • Sponsors Eiger BioPharmaceuticals

    • Most Recent Events

    • 21 Apr 2017 Results from the LOWER HDV program published in an Eiger BioPharmaceuticals, Inc. media release.
    • 21 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study has been presented at the The International Liver Congress 2017.
    • 06 Apr 2017 According to an Eiger BioPharmaceuticals, Inc. media release, data from the study will be presented at the European Association for the Study of the Liver (EASL) meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top